The stability of the 230U(VI)-DCP chelate complex was monitored for up to 84 days (4 half-lives of 230U) in human blood serum. No release of uranium from the chelate complex was observed. Our in vitro findings indicate that DCP is a promising candidate for chelation of the novel therapeutic alpha emitter 230U under physiological conditions. Presented on a Twelfth Conference on Cancer Therapy with Antibodies & Immunoconjugates, October 16-18, 2008, Parsippany.
B.03 Paper at an international scientific conference
COBISS.SI-ID: 22352167By the use of suitable bifunctional chelator, U230 could be conjugated to the carrier molecule forming a stable radioconjugate to be used in radiotherapy. In the present work, several complexing agents were taken into consideration, calix[n]arenes, n =6,8, and 2,9-dicarboxy-1,10-phenanthroline (DCP). The complexation property of proposed chelators was qualitatively and quantitatively evaluated by competitive binding experiments conducted in the presence of 2-(4-pyridylazo)resorcinol (PAR), Chelex 100 chelating resins and instant thin layer chromatography (ITLC).
F.01 Acquisition of new practical knowledge, information and skills
COBISS.SI-ID: 22562599The aim of this study is to assess in which extent the specific activity may be increased using a simulation approach, i.e. Bi chelation is quantitatively described considering the equilibrium reactions occuring in the radiolabelling medium. The parameters characterizing the interaction between Bi and the conjugate CHX-DTPA-IgG (kinetic and equilibrium parameters) were obtained using two displacement methods. Presented in a lecture at 7th International Conference on Nuclear and Radiochemistry, 24-29 August 2008, Budapest, Hungary.
B.03 Paper at an international scientific conference
COBISS.SI-ID: 22351143